Oculis Holdings Engaging in Key Investor Conferences This September
Oculis Holding AG (Nasdaq: OCS / Iceland: OCS), a leading biopharmaceutical company from Switzerland focusing on innovative solutions for ophthalmic and neuro-ophthalmic diseases, is gearing up for a month of critical investor outreach. Their management team will participate in several investor conferences throughout September, providing an excellent opportunity for investors to engage with the company directly and learn more about their groundbreaking work.
Upcoming Conference Schedule
Wells Fargo Healthcare Conference
The first major event on Oculis's agenda is the Wells Fargo Healthcare Conference, taking place from September 3-5 in Boston. Riad Sherif, M.D., the Chief Executive Officer, along with Chief Financial Officer Sylvia Cheung will represent the company. With insightful discussions planned, this conference is anticipated to lay the groundwork for future collaborations and insights into the biopharmaceutical landscape.
H.C. Wainwright 27th Annual Global Investment Conference
Following that, Oculis will take part in the H.C. Wainwright 27th Annual Global Investment Conference from September 8-10 in New York. A highlight of this conference will be a fireside chat with Dr. Sherif, scheduled for September 8 at 2:30 PM ET. This session promises to provide deep insights into the company’s strategic direction and ongoing projects, particularly focusing on their clinical pipeline that addresses significant medical needs.
Baird Global Healthcare Conference
Additionally, Oculis will be present at the Baird Global Healthcare Conference on September 9-10, also held in New York. Dr. Sherif will deliver a company update on September 9 at 3:45 PM ET, sharing developments and advancements within Oculis's innovative pipeline. Attendees will have the chance to ask questions, facilitating a more interactive engagement with the management team.
Pareto Securities 16th Annual Healthcare Conference
The following week, on September 16, Oculis will participate in the Pareto Securities 16th Annual Healthcare Conference in Stockholm. Páll Ragnar Jóhannesson, Chief Business Officer, is scheduled to present a company update at 9:15 AM CET. This will be an exceptional opportunity to connect with investors from various regions and discuss the latest advancements in their product candidates.
Leerink Partners Biopharma Summit
Later in the month, September 17-19 will see Oculis at the Leerink Partners Biopharma Summit in Healdsburg. Dr. Sherif will again represent the company, affirming his commitment to investor relations and transparency in business operations.
Opportunities for One-on-One Meetings
Throughout these conferences, Oculis will be available for one-on-one meetings, allowing personalized interactions between the management team and interested investors. Those who wish to schedule a meeting are encouraged to reach out through their representatives at the sponsoring institutions.
Oculis’s Commitment to Innovation
Oculis is dedicated to addressing the unmet medical needs in ophthalmic and neuro-ophthalmic conditions. Their late-stage clinical pipeline is immensely promising, featuring three core product candidates: OCS-01, OCS-05, and OCS-02. OCS-01 is currently undergoing pivotal registration studies aimed at becoming the first non-invasive topical treatment for diabetic macular edema.
On the other hand, Privosegtor (OCS-05), currently in Phase 2 trials, is targeting acute optic neuritis, underscoring the company's commitment to treatments with broad clinical applications. Lastly, Licaminlimab (OCS-02) is being developed for dry eye disease, utilizing a personalized medicine approach.
Headquartered in Switzerland and with operations extending into the U.S. and Iceland, Oculis boasts a robust management team supported by prominent international healthcare investors, ready to tackle the challenges in the biopharmaceutical industry.
Frequently Asked Questions
What is Oculis focusing on in the upcoming investor conferences?
Oculis will discuss their innovative solutions for ophthalmic and neuro-ophthalmic diseases, engaging directly with investors.
Who from Oculis will be attending the conferences?
Riad Sherif, M.D., CEO, and Sylvia Cheung, CFO, are among the key participants scheduled to attend.
Why are these conferences significant for Oculis?
These conferences provide Oculis an opportunity to showcase their advancements, connect with investors, and explore future collaborations.
What are the key product candidates Oculis is developing?
Oculis is developing OCS-01, OCS-05, and OCS-02, focusing on unmet needs in ophthalmic treatments.
How can investors participate in one-on-one meetings?
Interested investors can schedule meetings by contacting representatives at the sponsoring institutions during the conferences.
